Scottish Medicines Consortium Accepts VAZKEPA (icosapent ethyl) to Help Reduce Cardiovascular Risk for Patients in Scotland(1) - Seite 2

“The SMC’s acceptance and reimbursement of VAZKEPA is an important development for patients at high cardiovascular risk in Scotland, who will now have access to an innovative treatment option to improve their outcomes. Our UK team will now be focused on working with health boards to secure formulary inclusion and make VAZKEPA available to these patients as quickly as possible,” said Patrick Holt, President and CEO of Amarin. 

Amarin is working with Health Boards across Scotland to secure formulary inclusion and ensure that as many patients as possible among the eligible population will have access to VAZKEPA by the end of 2023.

The Company continues to advance its pricing and reimbursement discussions in a number of other European markets to drive patient access across the region and will share updates as these become available.

*Patient Access Schemes are confidential pricing agreements proposed by pharmaceutical companies to enable patient access to new medicines and treatments.  The Patient Access Scheme Assessment Group (PASAG) reviews and advises NHSScotland on the feasibility of proposed schemes for implementation. It operates separately from SMC. 

References

1. Scottish Medicines Consortium. Icosapent Ethyl (SMC2602). https://www.scottishmedicines.org.uk/medicines-advice/icosapent-ethyl- .... Accessed August 2023.
2. National Institute for Health and Care Excellence. Clinical Knowledge Summary. CVD risk assessment and management: What is the impact of CVD? May 2023. https://cks.nice.org.uk/topics/cvd-risk-assessment-management/backgrou .... Accessed August 2023.
3. British Heart Foundation. Scotland Factsheet. BHF. February 2023. https://www.bhf.org.uk/-/media/files/for-professionals/research/heart- .... Accessed August 2023 (from the UK).
4. British Heart Foundation. The CVD Challenge in Scotland. 2018. https://www.bhf.org.uk/for-professionals/healthcare-professionals/data .... Accessed August 2023. 

About Amarin
Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. We are committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk for patients worldwide. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world.